Waystar Considers Strategic Options, Including Potential Sale
Waystar explores a potential sale, just two years after its public market debut, amid a downturn in its market valuation.
Waystar, a healthcare software provider known for its payment management solutions used by hospitals and doctors, is contemplating a range of strategic options, including a possible sale. This move comes two years after the company went public in New York. The information, disclosed by seven sources familiar with the matter, indicates that Waystar has engaged investment bank Evercore to guide the process. However, the discussions are in preliminary stages, and there is no certainty that a sale will occur.
The Lehi, Utah, and Louisville, Kentucky-based company has seen its market value decline to approximately $4.8 billion following a 24% decrease in its share price this year. This drop is part of a broader selloff affecting the software sector. An auction process could provide insight into whether investor interest in software companies is reviving.
Market Strategy and Challenges
Waystar has tried to position itself as a technology-focused entity, offering solutions that automate and manage administrative tasks, distinguishing itself from traditional healthcare services that depend more on manual operations. This strategic positioning was intended to attract higher valuations typically associated with tech companies. Initially, this approach resonated with investors, propelling the stock from $20 to a high of $45 in 2025. However, concerns emerged regarding the potential impact of artificial intelligence advancements on the software industry, causing investor apprehension and affecting the stock's performance.
Ownership and Financial Backdrop
Waystar's journey began with a 2017 merger between Zirmed and Navicure, two healthcare revenue management firms. Its major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, which facilitated its public listing in 2024. EQT remains the largest shareholder with a 13% stake, followed by CPPIB at 10%, and BlackRock Institutional Trust Company at 8%, according to data from LSEG.
Despite the current financial challenges, the exploration of a sale suggests an opportunity to reassess the company's market position and value proposition. A successful transaction could potentially return Waystar to private ownership, allowing it to recalibrate its strategy away from the public eye.
Responses from Stakeholders
Neither Waystar nor Evercore has commented on the potential sale. Similarly, EQT and BlackRock have opted for silence, while CPPIB has not responded to requests for comments. The unfolding situation continues to be closely monitored by industry observers and investors alike, as it could signal broader trends in the healthcare software sector.